Gout is an inflammatory arthritis caused by monosodium urate crystal deposition in joints and periarticular tissues due to hyperuricemia. It presents with recurrent attacks of severe joint pain, swelling, redness, and warmth, classically affecting the first metatarsophalangeal joint. Untreated disease may lead to tophi, kidney stones, and chronic joint damage.
Q1 2026 sleep medicine trends include broader use of AI, expanding obstructive sleep apnea and narcolepsy treatments, and policy changes affecting reimbursement and access.
New research links GLP-1 drugs like Ozempic to increased scurvy risk through appetite suppression and poor nutrition. University of Florida researchers are testing a GLP-1 implant for obese cats as feline obesity affects nearly 60% of US cats.
Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07752810 |
Study of Safety, PK, and Efficacy of Multiple Ascending Doses of HZBio1 in Patients With Gout |
COMPLETED | PHASE1/PHASE2 |
| NCT07661030 |
The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time |
NOT_YET_RECRUITING | PHASE4 |
| NCT07657156 |
Musculoskeletal Ultrasound for Differentiating Rheumatoid and Gouty Arthritis |
NOT_YET_RECRUITING | |
| NCT07546643 |
Long-Term Risk of Gout in Living Kidney Donors |
COMPLETED | |
| NCT07535034 |
A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants |
RECRUITING | PHASE2 |
| NCT07504146 |
The Orienting Study |
RECRUITING | |
| NCT07490522 |
The Remote Monitoring of Gout Feasibility Study in Primary Care |
RECRUITING | NA |
| NCT07414394 |
Tigulixostat (IBI128) vs Febuxostat in Gout |
RECRUITING | PHASE3 |
| NCT07367971 |
Drug-Drug Interaction Study of ABP-671 in Gout Patients |
RECRUITING | PHASE1 |
| NCT07346079 |
Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares |
RECRUITING | PHASE4 |
